About Taos Therapeutics, Inc.
Our Mission
- Taos Therapeutics is developing the first pharmacological agonist + deterrence combination therapy for Alcohol Use Disorder (AUD) - a disease responsible for nearly 178,000 American deaths annually - significantly more than opioids and stimulants combined.
- Our sea change approach integrates proven generics to address the fundamental neurobiology of AUD for the first time while preventing relapse simultaneously.
- With around 14 million U.S. adults affected and less than 3% receiving pharmacotherapy, the market opportunity is massive, especially considering that payer reimbursement models have already been proven in opioid addiction.
- We are pursuing a 505(b)(2) FDA pathway, leveraging existing safety data for accelerated approval.
- This first-in-class combo drug has the potential for a direct line to M&A or IPO exits by establishing a new standard of care for AUD.